The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R.sup.1, X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in their synthesis, and to compositions containing them.